Immunosuppressive signature of cutaneous mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease

Journal of Infectious Diseases

Volumn 200, Issue 11, 2009, Pages 1675-1684

  Phillips, Richard ^a   Sarfo, Fred S ^a   Guenin Macé, Laure ^b   Decalf, Jérémie ^c   Wansbrough Jones, Mark ^d   Albert, Matthew L ^c   Demangel, Caroline ^b  

^a KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^b Unité Postulante de Pathogénomique Mycobactérienne Intégrée   (France)

^c INSTITUT PASTEUR   (France)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; CYTOTOXIN; MYCOLACTONE; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BURULI ULCER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE CULTURE; MALE; MYCOBACTERIUM ULCERANS; PRIORITY JOURNAL; TH1 CELL; TH17 CELL; TH2 CELL;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTITUBERCULAR; BACTERIAL TOXINS; BURULI ULCER; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOKINES; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYCOBACTERIUM ULCERANS; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES; TUBERCULOSIS, CUTANEOUS;

EID: 72849153503     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/646615     Document Type: Article

References (34)

1. Demangel C, Stinear TP, Cole ST. Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol 2009; 7:50-60.
2. World Health Organization. Buruli ulcer. World Health Organization Web site. http://www.who.int/gtb-buruli. Updated 2009.
3. Wansbrough-Jones M, Phillips R. Buruli ulcer: emerging from obscurity. Lancet 2006; 367:1849-1858
4. Etuaful S, Carbonnelle B, Grosset J, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacteriumulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005; 49:3182-3186
5. Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T. Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep 2008; 25:447-454 (Pubitemid 351725317) (Pubitemid 351725317)
6. George KM, Chatterjee D, Gunawardana G, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999; 283:854-857
7. Hong H, Coutanceau E, Leclerc M, Caleechurn L, Leadlay PF, Demangel C. Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop Dis 2008; 2:e325.
8. Snyder DS, Small PL. Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans. Microb Pathog 2003; 34:91-101.
9. George KM, Pascopella L, Welty DM, Small PL. A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 2000; 68:877-883
10. Coutanceau E, Decalf J, Martino A, et al. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med 2007; 204:1395-1403
11. Simmonds RE, Lali FV, Smallie T, Small PL, Foxwell BM. Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism. J Immunol 2009; 182:2194-2202
12. Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG, Pedrosa J. Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 2007; 75:3979-3988
13. Pahlevan AA, Wright DJ, Andrews C, George KM, Small PL, Foxwell BM. The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol 1999; 163:3928-3935
14. Coutanceau E, Marsollier L, Brosch R, et al. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol 2005; 7:1187-1196
15. Yeboah-Manu D, Peduzzi E, Mensah-Quainoo E, et al. Systemic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J Leukoc Biol 2006; 79:1150-1156 (Pubitemid 44835548) (Pubitemid 44835548)
16. Westenbrink BD, Stienstra Y, Huitema MG, et al. Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana. Clin Diagn Lab Immunol 2005; 12:125-129
17. Prevot G, Bourreau E, Pascalis H, et al. Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun 2004; 72:958-965 (Pubitemid 38166676) (Pubitemid 38166676)
18. Phillips R, Horsfield C, Kuijper S, et al. Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis. Clin Vaccine Immunol 2006; 13:253-257
19. Gooding TM, Kemp AS, Robins-Browne RM, Smith M, Johnson PD. Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. Clin Infect Dis 2003; 36:1076-1077
20. Gooding TM, Johnson PD, Smith M, Kemp AS, Robins-Browne RM. Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun 2002; 70:5562-5567
21. Gooding TM, Johnson PD, Campbell DE, et al. Immune response to infection with Mycobacterium ulcerans. Infect Immun 2001; 69:1704-1707
22. Phillips R, Horsfield C, Kuijper S, et al. Sensitivity of PCR targeting the IS2404 insertion sequence of Mycobacterium ulcerans in an assay using punch biopsy specimens for diagnosis of Buruli ulcer. J Clin Microbiol 2005; 43:3650-3656
23. Huygen K, Adjei O, Affolabi D, et al. Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol 2009; 198:69-77.
24. Vergne I, Fratti RA, Hill PJ, Chua J, Belisle J, Deretic V. Mycobacterium tuberculosis phagosome maturation arrest: mycobacterial phosphatidylinositol analog phosphatidylinositol mannoside stimulates early endosomal fusion. Mol Biol Cell 2004; 15:751-760
25. Nigou J, Gilleron M, Rojas M, Garcia LF, Thurnher M, Puzo G. Mycobacterial lipoarabinomannans: modulators of dendritic cell function and the apoptotic response. Microbes Infect 2002; 4:945-953 (Pubitemid 34775236) (Pubitemid 34775236)
26. Reed MB, Domenech P, Manca C, et al. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 2004; 431:84-87 (Pubitemid 39215112) (Pubitemid 39215112)
27. Dobos KM, Spotts EA, Marston BJ, Horsburgh CR Jr, King CH. Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease. Emerg Infect Dis 2000; 6:158-164
28. Guarner J, Bartlett J, Whitney EAS, et al. Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis 2003; 9:651-656
29. Sarfo FS, Phillips RO, Ampadu E, Sarpong F, Adentwe E,Wansbrough Jones M. Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans. Clin Vaccine Immunol 2009; 16:61-65
30. Johnson RC, Nackers F, Glynn JR, et al. Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS 2008; 22:901-903
31. Schutte D, Pluschke G. Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). Expert Opin Biol Ther 2009; 9:187-200.
32. Schutte D, Um-Boock A, Mensah-Quainoo E, Itin P, Schmid P, Pluschke G. Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis 2007; 1:e2.
33. Schutte D, Umboock A, Pluschke G. Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. Br J Dermatol 2009; 160:273-283
34. Beatty WL, Rhoades ER, Ullrich HJ, Chatterjee D, Heuser JE, Russell DG. Trafficking and release of mycobacterial lipids from infected macrophages. Traffic 2000; 1:235-247